S. Korea weighs label changes for Wegovy amid vision loss concerns
The U.S. Food and Drug Administration (FDA) has warned of the risk of vision loss associated with glucagon-like peptide-1 (GLP-1) drugs used to treat obesity and diabetes, including Wegovy and Ozempic, prompting South Korean health authorities to begin taking safety measures and reviewing changes to domestic drug approvals.
The Ministry of Food and Drug Saf..